Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL
- Joost C van Galen1,*,
- Jettie J F Muris1,*,
- Joost J Oudejans1,
- Wim Vos1,
- Cindy P E Giroth1,
- Gert J Ossenkoppele2,
- Arie P Otte3,
- Frank M Raaphorst1,4,
- Chris J L M Meijer1
- 1Departments of Pathology, VU Medical Center, Amsterdam, The Netherlands
- 2Departments of Haematology, VU Medical Center, Amsterdam, The Netherlands
- 3Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands
- 4Crucell Holland BV,Leiden, The Netherlands
- Correspondence to: Dr J J Oudejans Department of Clinical Pathology, VU Medical Center, De Boelelaan 1117, 1007 MB Amsterdam, The Netherlands; jj.oudejans{at}vumc.nl
- Accepted 22 June 2006
- Published Online First 12 July 2006
Abstract
Background: : Clinical outcome in patients with diffuse large B cell lymphomas (DLBCL) is highly variable and poorly predictable. Microarray studies showed that patients with DLBCL with a germinal centre B cell-like (GCB) phenotype have a better prognosis than those with an activated B cell-like (ABC) phenotype. The BMI1 proto-oncogene was identified as one of the genes present in the signature of the ABC type of DLBCL, associated with a poor prognosis.
Objectives: : (1) To investigate, in primary nodal DLBCL, the expression of BMI1 and its association with clinical outcome and DLBCL signature; (2) to look for an association between BMI1 expression and the expression of its putative downstream targets p14ARF and p16INK4a.
Results: : BMI1 expression was found to be associated with poor clinical outcome, but not clearly with an ABC-like phenotype of DLBCL. Expression of BMI1 was frequently, but not always, related to low levels of expression of p14ARF and p16INK4a.
Conclusion: : Expression of BMI1 is associated with an unfavourable clinical outcome of primary nodal DLBCL.
Footnotes
-
↵* These authors contributed equally to this study
-
Published Online First 12 July 2006
-
Competing interests: None.








